Education
About Us
Working with TipRanks
Follow Us
Vericel Corporation (VCEL)
:VCEL
VCEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$30.26 - $63.00
Previous CloseN/A
Volume83.17K
Average Volume (3M)669.25K
Market Cap
$1.59B
Enterprise Value$2.13B
Total Cash (Recent Filing)$116.88M
Total Debt (Recent Filing)$101.54M
Price to Earnings (P/E)252.0
Beta1.09
Next Earnings
Nov 06, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding50,460,205
10 Day Avg. Volume945,641
30 Day Avg. Volume669,253
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)9.19
Price to Sales (P/S)11.31
P/FCF Ratio-461.58
Enterprise Value/Market Cap1.34
Enterprise Value/Revenue8.54
Enterprise Value/Gross Profit11.62
Enterprise Value/Ebitda131.44
Forecast
1Y Price Target
$55.17Price Target Upside66.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Market PotentialMACI is expected to become a billion-dollar franchise, indicating strong potential for growth.
Product InnovationAdoption of Arthro will likely contribute to a near doubling of MACI procedure volumes driven by procedural efficiencies and growing patient awareness.
Bears Say
Revenue ConcernsShare pressure has been driven by concerns surrounding the revenue acceleration required to meet Street estimates.
Sales PerformanceVCEL reported 2Q25 sales of $63.2mn, which is 2% below consensus of $64.5mn.
Vericel News
VCEL FAQ
What was Vericel Corporation’s price range in the past 12 months?
Vericel Corporation lowest stock price was $30.26 and its highest was $63.00 in the past 12 months.
What is Vericel Corporation’s market cap?
Vericel Corporation’s market cap is $1.59B.
When is Vericel Corporation’s upcoming earnings report date?
Vericel Corporation’s upcoming earnings report date is Nov 06, 2025 which is in 49 days.
How were Vericel Corporation’s earnings last quarter?
Vericel Corporation released its earnings results on Jul 31, 2025. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.032 by $0.022.
Is Vericel Corporation overvalued?
According to Wall Street analysts Vericel Corporation’s price is currently Undervalued.
Does Vericel Corporation pay dividends?
Vericel Corporation does not currently pay dividends.
What is Vericel Corporation’s EPS estimate?
Vericel Corporation’s EPS estimate is >-0.01.
How many shares outstanding does Vericel Corporation have?
Vericel Corporation has 50,460,205 shares outstanding.
What happened to Vericel Corporation’s price movement after its last earnings report?
Vericel Corporation reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.032. Following the earnings report the stock price went down -14.068%.
Which hedge fund is a major shareholder of Vericel Corporation?
Currently, no hedge funds are holding shares in VCEL
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.17 (66.02% Upside)
$55.17 (66.02% Upside)
Blogger Sentiment
Bullish
VCEL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 7.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.9%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.69%
12-Months-Change
Fundamentals
Return on Equity
2.59%
Trailing 12-Months
Asset Growth
15.60%
Trailing 12-Months
Company Description
Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
VCEL Company Deck
VCEL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth across key segments and robust profitability metrics. Despite a few challenges such as Epicel cancellations and adjusted guidance for Burn Care, the overall business outlook remains positive with promising growth indicators, especially in the MACI segment.View all VCEL earnings summariesVCEL Stock 12 Month Forecast
Average Price Target
$55.17
▲(66.02% Upside)
Technical Analysis
Ownership Overview
1.06% Insiders
36.95% Mutual Funds
4.62% Other Institutional Investors
35.41% Public Companies and
Individual Investors